NCT00227279已完成3 期
A Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 634
- 试验地点
- 2
- 主要终点
- Recording of rhinoconjunctivitis symptoms
研究概览
简要总结
This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Recording of rhinoconjunctivitis symptoms
时间窗: Daily recordings during the entire grass pollen seasons 2007, 2008 and 2009
Recording of use of rescue medication
时间窗: Daily recordings during the entire grass pollen seasons 2007, 2008 and 2009
次要结局
- Quality of life(Weekly recordings during the entire grass pollen seasons 2007, 2008 and 2009)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Tolerability of ALK Grass Tablet in ChildrenAllergyNCT00310453ALK-Abelló A/S32
已完成
3 期
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)RhinoconjunctivitisConjunctivitisRhinitisAllergyNCT00550550ALK-Abelló A/S345
已完成
3 期
A Study Of Galcanezumab In Participants With Episodic Cluster HeadacheEpisodic Cluster HeadacheNCT02397473Eli Lilly and Company109
已完成
1 期
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's DiseaseCentral Nervous System DiseasesAlzheimer's DiseaseNCT00766363FORUM Pharmaceuticals Inc49
已完成
3 期
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin TherapyDiabetes Mellitus, Type 2NCT01215097Boehringer Ingelheim306